Cell & Gene Therapy CDMOs

Genezen (USA)

United States

Genezen (USA) is a leading cell and gene therapy CDMO founded in 2014, specializing in lentiviral, retroviral, and adeno-associated viral (AAV) vector manufacturing. The company operates a 60,000 sq ft cGMP facility in Fishers, Indiana and an 86,000 sq ft licensed facility in Lexington, Massachusetts. Genezen provides end-to-end services from preclinical through commercial manufacturing, with FDA registration and established manufacturing partnerships.

GenScript ProBio

China

GenScript ProBio is a leading biologics CDMO and subsidiary of GenScript Biotech Corporation, providing end-to-end services from discovery to commercialization. The company has raised $224 million in C-round funding, operates GMP plasmid and viral vector manufacturing facilities in Hopewell, New Jersey and Nanjing, China, and has established a manufacturing facility in Singapore. GenScript ProBio specializes in antibody discovery, cell and gene therapy manufacturing, and biologics development.

Hitech Health

Ireland

HiTech Health is an Irish CDMO specializing in GMP sterile manufacturing for advanced therapies including cell and gene therapies. The company provides clinical-scale aseptic fill-finish of vials and bags, Qualified Person (QP) release services for EU and UK markets, regulatory support, and end-to-end supply chain management. HiTech Health recently opened a new advanced therapy manufacturing center in Galway, Ireland.

Kincell Bio

United States

Kincell Bio is a specialized cell therapy CDMO based in the United States, dedicated exclusively to advancing autologous and allogeneic cell therapies from early clinical supply through pivotal and commercial launch. They provide process development, analytical development, and cGMP manufacturing services. The company operates manufacturing facilities in Research Triangle Park, North Carolina (32,800 sq ft acquired in 2024) and Gainesville, Florida. They have a strategic collaboration with Duke University School for cell and gene therapy innovation, and a partnership with RegCell to advance Treg cell therapies for autoimmune diseases.

Landmark Bio

United States

Landmark Bio is a cell and gene therapy CDMO based in Watertown, MA, focused on the development and manufacturing of advanced therapies. Offers end-to-end services including process and analytical development, formulation development, cGMP manufacturing, fill/finish, quality control testing, CMC consulting, and IND-enabling services. Acquired by Artis BioSolutions (a new genetic medicines CDMO) to form a comprehensive advanced therapy manufacturing platform. Facility is a 44,000 sq ft full-spectrum manufacturing site.

Made Scientific

United States

Made Scientific is a US-based cell therapy CDMO specializing in development and GMP manufacturing of cell-based therapies including T cells, NK cells, HSCs, MSCs, iPSCs, and TILs. The company provides services from pre-clinical support through Phase I-III clinical trials and commercial enablement, including process and analytical development, GMP cell banking, drug product manufacture, aseptic fill and finish, and QC lot release and stability testing. FDA-registered with FEI number and operations including API manufacture, analysis, labeling, manufacturing, and packaging.

Matica Biotechnology

United States

Matica Biotechnology is a US-based viral vector and gene therapy CDMO that leverages advanced technologies at its purpose-built cGMP facility. The company specializes in viral vector manufacturing from development to commercialization with expertise in process development, assay development, and cGMP manufacturing. Matica Bio operates across five sites worldwide and offers proprietary technologies including MatiMax cell lines, in-line process monitoring, and single-use technologies for AAV, lentivirus, and other viral vector platforms.

Miltenyi Bioindustries (Miltenyi Biotec)

Germany

Miltenyi Bioindustries (part of the Miltenyi Biotec group) is a German CDMO specializing in cell and gene therapy manufacturing. The company offers comprehensive CGT services including cell therapy process development, cell and gene therapy manufacturing, lentiviral vector production, and manufacturing technology platforms. Miltenyi has pioneered partnerships in cell and gene therapies for over 30 years and operates a global manufacturing network. The company has 2 FDA inspections on record and has conducted clinical trials in immunology and oncology.

Minaris Advanced Therapies

United States

Minaris Advanced Therapies (formerly Hitachi Chemical Advanced Therapeutics Solutions) is a global cell and gene therapy CDMO with 25+ years of autologous expertise. The company provides end-to-end GMP manufacturing and advanced testing services for gene-edited autologous (CAR-T, TCR-T), allogeneic (NK, HSC, iPSC), non-edited cell therapies, and vaccines. FDA-registered manufacturing site with FEI number.

Northway Biotech

Lithuania

Northway Biotech is a global end-to-end biologics CDMO specializing in protein-based biologics and gene therapies. The company operates state-of-the-art facilities in Vilnius, Lithuania (EU) and Waltham, Massachusetts (US), with 20+ years of technical expertise. Northway offers cell line development, process development, analytical development, and cGMP manufacturing of drug substances and drug products using both mammalian cell culture and microbial fermentation technologies.

NorthX Biologics

Sweden

NorthX Biologics is a Swedish CDMO specializing in advanced biologics and ATMPs (Advanced Therapy Medicinal Products). The company offers end-to-end services from process development to GMP manufacturing for recombinant proteins, viral vectors, plasmid DNA, cell therapy, extracellular vesicles, and mRNA. Recognized by the Swedish Government as an international competence center and innovation hub in 2021, NorthX has 30+ years of GMP manufacturing experience.

OBiO Tech (OBiO Technology)

China

OBiO Technology (Shanghai) Corp., Ltd (688238.SH) is a China-based biotechnology company and CRO/CDMO group focusing on cell and gene therapy. The company provides end-to-end offerings including process development, analytical method development, IND-enabling CMC, and clinical and commercial contract manufacturing of viral vectors, oncolytic viruses, and cell therapy products. OBiO operates a 10,000-square-meter GMP campus (Intelli-M PINE Site) with 29 GMP production lines.

OmniaBio Inc

Canada

OmniaBio Inc is Canada's largest cell and gene therapy CDMO, established by CCRM in 2022. The company provides end-to-end contract development and manufacturing services for autologous and allogeneic cell therapies, lentiviral vectors, and immunotherapies. Its Hamilton, Ontario facility integrates AI, automation, and robotics to enhance manufacturing efficiency and reduce costs.

Oxford Biomedica (OXB)

United Kingdom

Oxford Biomedica (OXB) is a global, quality- and innovation-led CDMO specializing in viral vector development and manufacturing for cell and gene therapy. With 25+ years of experience, OXB is the first and currently only FDA-approved CDMO for commercial production of lentiviral vectors for CAR-T therapy. The company operates GMP suites across three countries with extensive end-to-end capabilities in lentivirus, AAV, and adenovirus vectors.

Pharmicell Chemical

South Korea

Pharmicell Co., Ltd. is a South Korean biopharmaceutical company operating both chemical (API) and biologics (stem cell therapy) divisions, with CDMO services. The Chemical Business Unit in Ulsan (Onsan) manufactures oligonucleosides, pharmaceutical PEGs, and industrial advanced materials. The Bio division developed the world's first approved stem cell therapy (Hearticellgram AMI for cardiac repair) and provides CDMO services for advanced cell therapies with GMP facilities including Grade B/C clean rooms, virus testing labs, and microorganism testing labs. The company holds ISO 9001, ISO 14001 certifications and reported record revenue of 114 billion KRW in 2025. Pharmicell is expanding CDMO operations for regenerative medicine with capability to handle 7 cell types.

Recipharm AB

Sweden

Rechon Life Science AB is a subsidiary/entity within the Recipharm group, the global CDMO headquartered in Stockholm, Sweden. This entry represents the same Recipharm organization (same website: recipharm.com) with its extensive global manufacturing footprint of 15+ FDA-registered FEI numbers and 52 FDA inspections. The Perplexity research confirms Recipharm's specialization in oral solid dose, inhalation, sterile manufacturing, and HPAPI capabilities. Rechon may represent a specific Recipharm site or legacy entity. Duplicate of Recipharm AB entry -- capabilities are identical.

ReiThera Srl

Italy

ReiThera is an Italian CDMO dedicated to process development and GMP manufacturing of viral vectors for genetic vaccines and advanced therapy medicinal products (ATMPs). They have extensive expertise in developing scalable processes for Adeno-Associated Vectors (AAV), Lentivirus, Adenoviral vectors (AdV), Modified Vaccinia Ankara, and Herpes Simplex Vectors. Their state-of-the-art facility in Rome features stirred-tank bioreactors at 50L, 200L, 1000L, and 2000L scales, fixed-bed bioreactors, a filling suite, and quality control laboratories. They also develop their own vaccine candidates (e.g., GRAd-COV2).

Roslin Cell Therapies Ltd

United Kingdom

Roslin Cell Therapies Ltd (trading as RoslinCT) is a leading global CDMO focused exclusively on advanced cell therapies. Originally spun out from the Roslin Institute in Edinburgh, Scotland, the company merged with Lykan Bioscience in 2022 and received significant investment from GHO Capital. RoslinCT provides contract development and GMP manufacturing services for cell therapy products, operating facilities in Edinburgh, UK and Hopkinton, MA, USA.

Scorpius BioManufacturing

United States

Scorpius BioManufacturing is a US-based biologics CDMO focused on mammalian, microbial, and cell therapy manufacturing. The company provides cGMP manufacturing, bioanalytical, and process development services from its San Antonio, Texas facility. Note: Tivic Health acquired manufacturing assets from Scorpius, and the company has undergone corporate restructuring under Scorpius Holdings / NightHawk Biosciences.

SCTbio

Czechia

SCTbio is a Czech CDMO specializing in cell and gene therapy (ATMP) manufacturing, spun out from SOTIO. The company provides cGMP production of cell-based therapies and retroviral/lentiviral vectors from its 2,000 sqm facility in Prague, Czech Republic. SCTbio has specialized expertise in dendritic cell therapeutics, CAR-T, and viral vector production, supported by a global network of 150 apheresis collection centers.

SEQENS

Canada

SEQENS is a global integrated CDMO and specialty ingredients leader with 15 production sites across 9 countries and 5 R&D centers. The company manufactures custom and generic APIs, intermediates, excipients, custom lipids for drug delivery (mRNA/siRNA, LNP), HPAPIs, and specialty chemicals. SEQENS also operates CELLforCURE, an EMA-authorized CDMO for Advanced Therapy Medicinal Products (ATMPs/Cell & Gene Therapy). The company serves 1,500+ customers in 80+ countries with approximately 2,700 employees and ~1B EUR revenue.

Taav Biomanufacturing Solutions

United Kingdom

TAAV Biomanufacturing Solutions is a CDMO specializing in enzymatic DNA production (neDNA) as a critical starting material for AAV (adeno-associated virus) gene therapy manufacturing. Their core product is neDNA -- a synthetic, linear, double-stranded, closed-ended DNA molecule designed as an alternative to plasmids for transfection-based AAV production. The company works with biopharma companies, research centers, and entities developing AAV-based gene therapies. TAAV is part of the Viralgen/AskBio (Bayer) ecosystem, based in Spain with UK registration.

Takara Bio

Japan

Takara Bio (a Takara Holdings company) is a Japanese biotechnology company with a significant CDMO business for cell and gene therapy products. They operate the Center for Gene and Cell Processing (CGCP) at their headquarters in Shiga, Japan, which they have expanded to accommodate a variety of advanced therapy modalities. Their CDMO services cover comprehensive cellular and gene therapy product manufacturing and quality testing. Takara Bio also supplies reagents and instruments (research tools business) but the CDMO division is a distinct contract manufacturing operation. They have GMP-grade manufacturing capabilities in both Japan and Goteborg, Sweden (Takara Bio Europe AB).

Theragent Inc

United States

US-based comprehensive CDMO focused on advancing next-generation cell- and tissue-based therapies, from R&D to cGMP manufacturing. Located in Arcadia, California. Has partnerships with CellVax Therapeutics (first manufacturing collaboration, Phase 2 trial for FK-PC101), Pluristyx (iPSC-derived therapies), and Insight68 (Pharma 4.0 AI software). Works with iPSC, NK cells, T cells, and CAR-T for allogeneic and autologous therapies. Expanding leadership team with experienced biopharma executives.

Touchlight

United Kingdom

Touchlight is a UK-based CDMO pioneering enzymatic GMP DNA production using its proprietary cell-free dbDNA technology. Founded in 2007 and based in London, the company manufactures high-purity DNA for genetic medicines across applications including mRNA, AAV viral vectors, lentiviral vectors, gene editing, DNA vaccines, and non-viral gene therapy. Touchlight holds a world-first MHRA GMP certification for synthetic DNA manufacturing and has 9 programs in the clinic using dbDNA.

Vector BioMed

United States

Vector BioMed is a U.S.-based public benefit corporation and CDMO specializing in lentiviral vector design and manufacturing for cell and gene therapies. Launched following $15M in funding, the company provides essential lentiviral vector capabilities using their proprietary LENTIVERSE platform. They produce high-titer (>10^9 TU/mL) lentiviral vectors using a serum-free, chemically-defined process. Key differentiators include algorithm-optimized vector design, rapid turnaround (months from onboarding to GMP batch release), modular pre-validated systems to reduce costs and avoid royalty-based constraints, and a focus on making advanced therapies accessible in lower-resource settings. They partner with CIRM (California Institute for Regenerative Medicine) on lentiviral vector manufacture.

3PBiovian

Finland

3P Biovian is a global biologics CDMO providing end-to-end services from early-stage development to commercialization. They specialize in proteins, viral vectors, plasmid DNA, and cell therapy products with cGMP manufacturing facilities in Turku, Finland, and Pamplona-Noain, Spain. The company has invested over 50 million euros in facility expansion.

adthera bio limited

United Kingdom

Adthera Bio Limited is a UK-based cell and gene therapy CDMO that recently emerged from stealth with venture funding from Delin Ventures. They position themselves as a digital-first CDMO partner for cell and gene therapy manufacturing. Their website was not accessible at time of data collection (domain not yet pointed), indicating they are in early-stage operations.

AMPAC Analytical is part of SK pharmteco, a major integrated CDMO providing custom small molecule API development and manufacturing, viral vector and gene therapy CDMO services, and comprehensive analytical testing. SK pharmteco operates FDA/EMA/PMDA-inspected facilities across the US, Korea, Ireland, and France with capabilities spanning from clinical trials through commercial scale manufacturing.

Applied StemCell

United States

Applied StemCell is a CRO/CDMO based in the United States specializing in cell and gene therapy. The company provides genome engineering services using CRISPR, Mad7, and their proprietary TARGATT large cargo knock-in platform. They operate a cGMP manufacturing facility that supports iPSC-based and antibody-based advanced therapeutics, from cell line development through process development and GMP manufacturing.

Cobra Biologics is an international CDMO specializing in plasmid DNA, viral vectors, and aseptic pharmaceutical manufacturing, now part of Charles River Laboratories following the acquisition of Cognate BioServices. The company operates facilities in the UK and Sweden (Matfors), providing clinical and commercial-scale manufacturing of gene therapy products, with expanded viral vector suite capabilities and collaborations in COVID-19 vaccine manufacturing.

Comprehensive Cell Solutions (NYBCe)

United States

Comprehensive Cell Solutions (CCS) is a business unit of the New York Blood Center Enterprises focused on cell and gene therapy contract development and manufacturing. CCS provides critical manufacturing capacity to early-stage developers, offering services including cell sourcing, apheresis, GMP/GTP manufacturing, cryopreservation, process development, analytical development, and quality control. The company has partnered with ProBio and ExCellThera to expand its manufacturing and collaboration capabilities.

DINAMIQS

Switzerland

DINAMIQS is a Swiss CDMO for AAV and lentiviral vector manufacturing, part of the Siegfried group since May 2023. In September 2025 they opened a 2,500 sq m cGMP facility in Zurich's Bio-Technopark for viral vector gene therapy manufacturing, supporting R&D through commercial scale. They licensed ExcellGene's HEKExpress and HEK2Express cell line technologies for GMP viral vector production.

Dr.PARK Co., Ltd.

South Korea

Dr.PARK Co., Ltd. is a South Korean biologics CDMO specializing in protein bioproduction and large-scale cell and gene therapy manufacturing. The company has partnered with Thermo Fisher Scientific to equip a new viral vector manufacturing facility with advanced bioprocessing solutions.

ElevateBio (BaseCamp)

United States

ElevateBio is a US-based genetic medicines company whose BaseCamp division operates as a cGMP manufacturing CDMO for cell therapy, gene therapy, and mRNA products. BaseCamp provides development and manufacturing services from concept through commercialization, leveraging state-of-the-art facilities and proprietary technologies. The company has achieved six consecutive years of revenue growth and holds ICMC certification for its manufacturing operations.

Eurofins Biopharma Services (CDMO)

Australia

Eurofins Biopharma Services CDMO is a division of Eurofins Scientific offering integrated API and drug product outsourcing services across small molecules and biologics. The company provides services from early-stage development through commercial manufacturing including highly potent drug development, sterile manufacturing/fill-finish, lyophilization, and biologics development through its Alphora brand.

eXmoor Pharma Concepts Ltd

United Kingdom

eXmoor Pharma is a UK-based integrated cell and gene therapy CDMO with over 20 years of consultancy expertise embedded across CMC development, process development, GMP manufacturing, and commercialization. The company operates a 65,000 sq ft facility near Bristol with four Grade C process-agnostic GMP clean rooms, supporting viral vectors, autologous and allogeneic cell therapies, and RNA technologies.

ExoXpert

Germany

ExoXpert, a subsidiary of EXO Biologics, is a Belgium-based CDMO specialized in exosome manufacturing for clinical trials. The company operates a 1,000 sq m GMP-certified facility and offers its clinically proven ExoPulse platform for MSC-based exosome production, including off-the-shelf exosome vials and custom GMP manufacturing services.

Flash BioSolutions

France

Flash BioSolutions (also branded as RNAlead) is a French CDMO specializing in the industrial-scale production of DNA and RNA vectors for gene therapy, cell therapy, vaccination, and genome editing applications. Its proprietary FlashRNA technology combines lentiviral cell transfer functions with bacteriophage RNA packaging for multi-RNA delivery, with GMP production initiated for next-generation mRNA vaccines and therapies.

GC Biopharma

South Korea

GC Biopharma is a South Korean biopharmaceutical company specializing in vaccines, plasma-derived therapies, and biologics. The company provides Vial and Pre-Filled Syringe (PFS) Fill & Finish CMO services and drug product (DP) manufacturing as CDMO services. GC Biopharma has established an mRNA production facility at its Hwasun plant and operates multiple manufacturing sites including Ochang, Hwasun, and Eumseong plants.

Guangzhou Packgene Biotechnology Co Ltd (PackGene)

China

PackGene Biotech is a Chinese cell and gene therapy CRO and CDMO providing comprehensive AAV, lentivirus, mRNA, and plasmid services from discovery through GMP manufacturing. The company operates a 120,000 sq ft GMP facility for viral vector production and has served over 1,000 clients globally with more than 50,000 projects delivered.

Histocell

Spain

Histocell is a Spanish clinical-stage biopharmaceutical company and CDMO specializing in regenerative medicine and advanced therapy medicinal products (ATMPs). Based in the Basque Country, the company develops and manufactures cell therapy products from iPSCs, MSCs, secretomes, and exosomes. Histocell recently achieved GMP certification from AEMPS for iPSC manufacturing in partnership with REPROCELL, and has produced over 350 GMP batches treating approximately 300 patients from its 800 m2 EMA-registered facility.

Kolon Biotech

South Korea

Kolon Biotech Inc. is a South Korean cell and gene therapy CDMO, part of the Kolon Group. They operate 17,000 sqm of facilities designed for both development and GMP manufacturing of cell and gene therapy products. Their B1 plant supports multiple simultaneous products and development projects, while B2 is optimized for mass production targeting global markets with flexible customization. Kolon Biotech is FDA-registered (FEI 3019016602) for analysis, API manufacture, labeling, manufacturing, and packaging. They offer end-to-end CDMO services aimed at shortening time-to-market, including a 2D Automated Closed Platform for large-scale adherent cell manufacturing.

Memel Biotech, UAB

Lithuania

Memel Biotech UAB is a Lithuanian CDMO providing GMP manufacturing services for Advanced Therapy Medicinal Products (ATMPs) for the clinical research community. Launched by the Cureline Group in 2024, Memel Biotech offers ATMP development and manufacturing services from facilities in Lithuania (Klaipeda and Vilnius). The company collaborates with Therabest on exosome-based cell therapies. Memel Biotech focuses on cell and gene therapy manufacturing at clinical scale, positioning itself as a new CDMO in the Baltics for the ATMP sector.

Reliance Life Sciences (RLS), part of Reliance Industries, is a premier Indian biotechnology company providing contract manufacturing and development services across pharmaceuticals and biosimilars. They have FDA-registered manufacturing facilities with 7 FDA-approved products (injectables, powders, tablets). Their capabilities span API manufacturing, formulation development, biologics/biosimilar manufacturing, and cell and gene therapy R&D. They are a vertically integrated biotech company with 1,000-5,000 employees, offering CDMO services alongside their own product portfolio.

Duplicate entry for VGXI Inc (see companyId 58cac364). Same company -- leading plasmid DNA CDMO in Texas. Same website URL (vgxii.com). Same capabilities, facilities, and services.

BioIVT

United States

BioIVT is a global provider of biological research products and services, specializing in biospecimen solutions, ADME-Tox in vitro models, control matrices, and diagnostic solutions for drug and diagnostic development. They have opened a GMP-compliant facility for cell and gene therapy R&D materials but are primarily a biospecimen/research services company, not a drug manufacturer.

CHA Biotech is a South Korean biotechnology company within the CHA Hospital Group, established in 2002 with over 20 years of expertise in stem cell research and cell and gene therapy. The company operates a global CGT CDMO network through its US subsidiary Matica BioLabs, with GMP facilities in Korea (CHA Bundang Medical Center, Pangyo Techno Valley) and the US (Texas). CHA Biotech offers viral vector production (500L capacity for clinical trials) and has secured multiple CDMO contracts for CAR-T and organoid therapies.